References
- Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577-589.
- Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising blood biomarkers for clinical use in Alzheimer's disease: a focused update. J Clin Neurol 2022;18:401-409.
- Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst) 2019;11:730-743.
- Mattsson N, Andreasson U, Zetterberg H, Blennow K; Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557-566.
- Lee EH, Kwon HS, Koh SH, Choi SH, Jin JH, Jeong JH, et al. Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimers Res Ther 2022;14:6.
- Altmann P, Ponleitner M, Rommer PS, Haslacher H, Mucher P, Leutmezer F, et al. Seven day preanalytical stability of serum and plasma neurofilament light chain. Sci Rep 2021;11:11034.
- Hviid CV, Knudsen CS, Parkner T. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand J Clin Lab Invest 2020;80:291-295.
- Syed YY, Deeks E. [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment. CNS Drugs 2015;29:605-613.
- Harp CT, Hendricks R, Fischer SK, Brumm J, Herman AH. Neurofilament light chain (NfL) levels in CSF, serum, and plasma of healthy donors using the Quanterix NfL Advantage KitTM (P1.9-032). Neurology 2019;92:P1.9-032.